Skip to content

Clinical trials

Neuroblastoma trials with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neuroblastoma Status: Unknown status Clear all

55 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20021
20032
20044
20052
20061
20072
20083
20092
20113
20121
20132
20141
20154
20163
20171
20181
20193
20213
20233
20242

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status55

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Children's Cancer and Leukaemia Group10
Milton S. Hershey Medical Center3
National Taiwan University Hospital3
German Society for Pediatric Oncology and Hematology GPOH gGmbH2
Samsung Medical Center2
St. Anna Kinderkrebsforschung2
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine2
Affiliated Hospital of Nantong University1
American College of Radiology Imaging Network1
Assiut University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neuroblastoma55
Sarcoma7
Lymphoma6
Recurrence6
Burkitt Lymphoma5
Dendritic Cell Sarcoma, Interdigitating5
Neoplasms5
Precursor Cell Lymphoblastic Leukemia-Lymphoma5
Wilms Tumor5
Neuroectodermal Tumors, Primitive, Peripheral4

Trials

Showing 76 to 55 of 55. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.